MK-1775

Target: This ligand targets WEE1 checkpoint kinase in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for WEE1 checkpoint kinase. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings WEE1 checkpoint kinase into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC-Mediated Kinase Degradation: MK-1775 can be used as a PROTAC ligand to recruit a target kinase to an E3 ligase, enabling ubiquitination and proteasomal removal. This application supports testing how ligand engagement and linker geometry influence ternary complex formation, degradation kinetics, and pathway suppression in kinase-driven signaling models.

• E3 Ligase Recruitment Optimization: Pairing MK-1775 with alternative E3 ligase-binding moieties supports systematic evaluation of degradation efficiency across ligase families. Researchers can compare degradation potency, selectivity, and off-target ubiquitination by varying E3 ligands, thereby identifying the most productive recruitment strategy for MK-1775–directed chimeras.

• Structure-Guided Linker Tuning: MK-1775–based PROTACs are well suited for structure-guided linker optimization to maximize productive contacts within the ternary complex. By adjusting linker length, rigidity, and attachment points, experiments can map how conformational constraints affect target engagement, ubiquitin transfer, and sustained protein loss.

• Mechanism-of-Action Profiling: MK-1775 PROTAC constructs can be used to dissect degradation mechanisms, including dependence on the ubiquitin-proteasome system and sensitivity to pathway perturbations. Quantifying target protein depletion alongside downstream phosphorylation changes helps distinguish degradation-driven effects from occupancy-only pharmacology in cellular assays.

MK-1775 is a WEE1 kinase target ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of MK-1775 is characterized by primary or secondary amine/basic nitrogen centers; phenol or alcohol functionality; heteroaromatic protein-recognition scaffold. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.